Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Consensus Rating of “Moderate Buy” from Brokerages

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has received a consensus rating of “Moderate Buy” from the seventeen brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $205.6667.

JAZZ has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Bank of America increased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Needham & Company LLC lifted their target price on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, UBS Group reiterated a “neutral” rating and set a $188.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the completion of the sale, the director owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. This trade represents a 16.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the transaction, the chief accounting officer directly owned 7,012 shares in the company, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 123,791 shares of company stock worth $21,991,850. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Philip James Wealth Mangement LLC grew its holdings in Jazz Pharmaceuticals by 42.0% during the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock valued at $1,676,000 after purchasing an additional 4,675 shares during the period. State of Alaska Department of Revenue lifted its holdings in Jazz Pharmaceuticals by 75.1% during the second quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after purchasing an additional 24,850 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $1,100,000. Wedge Capital Management L L P NC bought a new position in shares of Jazz Pharmaceuticals in the third quarter worth approximately $27,834,000. Finally, Voya Investment Management LLC increased its stake in shares of Jazz Pharmaceuticals by 67.1% in the first quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock worth $6,996,000 after purchasing an additional 22,628 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ JAZZ opened at $169.41 on Tuesday. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $182.99. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The firm has a 50-day moving average of $167.01 and a 200 day moving average of $139.74. The stock has a market cap of $10.29 billion, a P/E ratio of -27.91, a price-to-earnings-growth ratio of 0.75 and a beta of 0.27.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.